Kelly Chin, M.D. Professor School Medical School Department Internal Medicine You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Kelly Chin, M.D., is a Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of the Division of Pulmonary and Critical Care Medicine. It's very rewarding as a physician to help patients improve with effective treatment options and impact their life in that way. Dr. Chin holds a bachelor's degree with honors in biology from the University of Texas at Austin. She earned her medical degree and completed training in internal medicine at UT Southwestern Medical Center and completed a fellowship in pulmonary and critical care medicine at the University of California San Diego. She also completed both a master's degree in clinical sciences with honors from UTSW through the UT Southwestern Clinical Scholar's Program. She is currently serving as Director, Pulmonary Hypertension Research and as the Medical Director for the Heart Lung Clinic at UT Southwestern. She previously served as the Director of the UTSW Pulmonary Hypertension Program from 2010-2023. Dr. Chin is board certified in pulmonary medicine and in critical care medicine. Her clinical interests include pulmonary hypertension and chronic thromboembolic hypertension, and she has served as a principal investigator and as a steering committee member for multiple phase II, III and IV clinical trials in pulmonary hypertension. Dr. Chin is listed in Texas Monthly's Super Doctor and D Magazine's Top Doctors Education Medical School UT Southwestern Medical School (1996) Residency UT Southwestern Medical Center (2000), Internal Medicine Fellowship University of California at San Diego School of Medicine (2005), Pulmonary Diseases & Critical Care Medicine Research Interest Pulmonary Hypertension Publications Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial Author Collaboration TS, Frantz RP, McLaughlin VV, Sahay S, Escribano Subías P, Zolty RL, Benza RL, Channick RN, Chin KM, Hemnes AR, Howard LS, Sitbon O, Vachiéry JL, Zamanian RT, Cravets M, Roscigno RF, Mottola D, Osterhout R, Bruey JM, Elman E, Tompkins Ca, Parsley E, Aranda R, Zisman LS, Ghofrani HA, Adir Y, Baillie T, Baratz D, Burger C, Chakinala MM, Cifrián Martínez JM, Delcroix M, Dwyer N, Elwing JM, Fisher M, Franco V, Grünig E, Highland K, Hill N, Hirani N, Hoeper M, Jansa P, Keogh A, Kingrey J, Lopez-Meseguer M, McConnell JW, Mehta S, Melendres-Groves L, Opitz C, Pepke-Zaba J, Pillutla P The Lancet Respiratory Medicine 2024 Jul 12 523-534 Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset Channick R, Chin KM, McLaughlin VV, Lammi MR, Zamanian RT, Turricchia S, Ong R, Mitchell L, Kim NH Cardiology and Therapy 2024 Jun 13 315-339 Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER-MRI studies Lawrie A, Chin K, Fong YL, Gargano C, Gitton X, He C, Kiely DG, Zhou L, Zhou L, Maron BA, Quinn D, Rosenkranz S, Stamatiadis D, Toshner M, Wilkins MR, Howard L, Preston IR Pulmonary Circulation 2024 Apr 14 Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies Kim NH, Chin KM, McLaughlin VV, DuBrock H, Restrepo-Jaramillo R, Safdar Z, MacDonald G, Martin N, Rosenberg D, Solonets M, Channick R Pulmonary Therapy 2024 Mar 10 85-107 Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) McLaughlin V, Farber HW, Highland KB, Hemnes AR, Chakinala MM, Chin KM, Han M, Cho M, Tobore T, Rahman M, Kim NH Journal of Heart and Lung Transplantation 2024 Feb 43 272-283 Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension Grünig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, Rofael H, Chin KM Journal of the American College of Cardiology 2024 Jan 83 473-484 Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities McLaughlin VV, Sitbon O, Chin KM, Galiè N, Hoeper MM, Kiely DG, MacDonald G, Martin N, Mathai SC, Peacock A, Tawakol A, Torbicki A, Noordegraaf AV, Rosenkranz S European Journal of Heart Failure 2024 Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy Abu-Rmaileh M, Mirza O, Patel C, Shah T, Hardin EA, Bartolome SD, Chin KM Pulmonary Circulation 2023 Apr 13 Pregnancy and Congenital Heart Disease-Associated Pulmonary Hypertension: Are Outcomes Improving? Chin KM, Santiago-Munoz P Circulation 2023 Feb 147 562-564 Disentangling the Pulmonary Capillary Wedge Pressure from the Pulmonary Artery Pressure as the Hemodynamic Underpinning of Bendopnea Thibodeau JT, Ravipati G, Pham DD, Ayers CR, Hardin EA, Chin KM, Grodin JL, Drazner MH Circulation: Heart Failure 2023 Feb 16 E010169 Results 1-10 of 74 1 2 3 4 5 Next Last Books Featured Books Pulmonary Hypertension. In Murray and Nadel's Textbook of Respiratory Medicine Chin KM, Channick RN. (2015). Chronic Thromboembolic Pulmonary Hypertension. In Pulmonary Vascular Disease Chin K, Fedullo P. (2006). Surgical Treatments. In Pulmonary Hypertension. A Patient's Survival Guide Chin KM, Torres F (2011). Honors & Awards Finalist, Alfred Soffer Research AwardACCP Original Research Award 2007 Southwestern Medical Foundation Medical School Scholarship UT Southwestern Clinical Scholar, Class of 2011 Professional Associations/Affiliations American College of Chest Physicians American Medical Association American Thoracic Society Pulmonary Hypertension Association
